73980-24-2

Basic information

• Product Name: [4-(4-Chloro-phenoxy)-phenyl]-oxo-acetic acid ethyl ester
• Synonyms: [4-(4-Chloro-phenoxy)-phenyl]-oxo-acetic acid ethyl ester
• CAS NO: 73980-24-2
• Molecular Weight: 304.73
• Mol File: 73980-24-2.mol
• Article Data: 4

Chemical Properties

• CAS DataBase Reference: [4-(4-Chloro-phenoxy)-phenyl]-oxo-acetic acid ethyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: [4-(4-Chloro-phenoxy)-phenyl]-oxo-acetic acid ethyl ester(73980-24-2)
• EPA Substance Registry System: [4-(4-Chloro-phenoxy)-phenyl]-oxo-acetic acid ethyl ester(73980-24-2)

Safety Data

• Hazardous Substances Data: 73980-24-2(Hazardous Substances Data)

Upstream product

• 7005-72-3 4-chlorodiphenyl ether 
• 4755-77-5 Ethyl oxalyl chloride 

Downstream Products

• 1337644-43-5 C₁₄H₁₄ClNO₂ 
• 1440063-23-9 C₂₁H₁₆ClF₂NO₃ 
• 1440059-66-4 C₂₁H₁₅Cl₂F₂NO₂ 
• 1440060-46-7 C₂₁H₁₄ClF₂NO₂ 
• 1440061-84-6 C₁₆H₁₄ClNO₄ 
• 74649-69-7 Ethyl 2-chloro-2-<4-(4-chlorophenoxy)phenyl> acetate 
• 85259-38-7 [4-(4-Chloro-phenoxy)-phenyl]-hydroxy-acetic acid ethyl ester 

Relevant articles and documents

CERAMIDE GALACTOSYLTRANSFERASE INHIBITORS FOR THE TREATMENT OF DISEASE

Described herein are compounds, methods of making such compounds, pharmaceutical compositions and medicaments containing such compounds, and methods of using such compounds to treat or prevent diseases or disorders associated with the enzyme ceramide galactosyltransferase (CGT), such as, for example, lysosomal storage diseases. Examples of lysosomal storage diseases include, for example, Krabbe disease and Metachromatic Leukodystrophy.

Studies on antihyperlipidemic agents. I. Synthesis and hypolipidemic activities of phenoxyphenyl alkanoic acid derivatives

The alkanoic acids containing phenoxyphenyl moiety at ω-position were prepared and tested for hypolipidemic property. Some of the compounds showed hypoglycemic activity besides hypolipolipidemic one. Further study on the selected compound, 3-[4-(4-chlorophenoxy)benzoyl]propionic acid (8) revealed that it increased insulin sensitivity of adipose tissue of obese and diabetic mice (KKA(y)). The structure-activity relationship was discussed briefly.